CompoAtlas

Meno Control

Meno Control, licence 80097376: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Natural health product licensed in Canada

Other names
Menopause Control, Méno Control, Ménopause Control
Licence holder
Martin Allard Nutraceutique Inc.
NPN or DIN-HM
80097376
Status
Inactive licence
Licence date
3 March 2020
Revision date
Not provided
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Extrait d'isoflavone de soja

Source : Glycine max - Graine

Potency : 3.9 mg EAI Génistéine/génistine

Not specifiedNot calculated
Extrait d'isoflavone de soja

Source : Glycine max - Graine

Potency : 38.5 mg Equivalent Aglycones d'Isoflavones

100.0 mgNot calculated

Non-medicinal ingredients

Stéarate de magnésium, farine de riz, Hypromellose, L-Leucine

PopulationAgeQuantity per servingFrequency
Adultesminimum: 19.0 Année(s)1.0 Capsule3.0 Tous les jours

Uses authorised in Canada

Utilisé en phytothérapie pour aider à soulager les symptômes reliés à la ménopause, tels que les bouffées de chaleur. Pourrait aider à réduire/atténuer la perte de la densité minérale osseuse (DMO) chez les femmes en post-ménopause lorsque combiné à un apport suffisant de calcium et de vitamine D.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80097376

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Enter to analyse, Shift+Enter for a new line